Spectral AI advances DeepView burn diagnostics after FDA nod

Spectral AI received FDA De Novo classification for its DeepView burn wound diagnostic system, authorizing commercial sales in the US and establishing a new device category. The company is launching commercially with device placements and recurring revenue, targeting burn centers and expanding internationally, backed by over $250 million in government funding.

This Wire brief sits within Fusion42's coverage of Digital Health.